Derazantinib - ArQule

Drug Profile

Derazantinib - ArQule

Alternative Names: ARQ-087

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule
  • Class Amines; Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase I Solid tumours

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 01 Aug 2017 Phase-III clinical trials in Cholangiocarcinoma (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in USA (PO) (NCT03230318)
  • 03 Jun 2017 Updated efficacy data from a phase I/II trial in Cholangiocarcinoma released by ArQule
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top